Overdose deaths are falling and integration rules are finally modernized, but Medicaid cuts and a SAMHSA overhaul threaten the financing that makes integration work.
Key Takeaways
- The legal scaffolding for integration was rebuilt in three years. Between 2023 and 2026, federal regulators eliminated the buprenorphine X-waiver, modernized opioid treatment program rules for the first time in two decades, aligned 42 CFR Part 2 with HIPAA, and made the Certified Community Behavioral Health Clinic model a permanent Medicaid option. The clinical and privacy barriers that kept addiction care siloed from the rest of medicine are now, on paper, largely gone.
- Access expanded faster than uptake. Removing the X-waiver multiplied the pool of clinicians who may prescribe buprenorphine from roughly 130,000 to about 1.8 million, yet peer-reviewed analyses found dispensing barely moved in the months that followed. Structural permission is not the same as a clinician who is willing, trained, and paid to treat.
- The financing foundation is contracting as the tools mature. The One Big Beautiful Bill Act cuts roughly $1 trillion from Medicaid over a decade, and the 2025 reorganization folding SAMHSA into a new Administration for a Healthy America has unsettled the grant infrastructure that pays for innovation. Medicaid funds about a quarter of all behavioral health spending, so the contraction lands directly on integration.
- The data still points the right way, for now. Overdose deaths have fallen for three consecutive years, and the integration models with aligned payment, including collaborative care and CCBHCs, are growing where states fund them. Whether that progress holds depends less on the clinical evidence than on the budgets being written in Washington and the state capitals.
For the first time in the modern history of the overdose crisis, the numbers are moving in the right direction. The CDC’s National Center for Health Statistics estimates roughly 69,973 drug overdose deaths in 2025, down about 14 percent from the prior year and the third consecutive annual decline since deaths peaked in 2022. That follows a fall of nearly 27 percent in 2024, from about 110,000 deaths in 2023 to roughly 80,000. The reasons are contested and almost certainly multiple: naloxone saturation, a shifting illicit drug supply, harm reduction, and treatment expansion all have their advocates. What is less contested is that the machinery for delivering substance use disorder treatment, and for stitching it into the rest of behavioral and physical health care, looks very different than it did at the start of the decade. The question for 2026 is no longer whether the country knows how to integrate addiction care. It is whether the money and the agencies that pay for integration will still be standing when providers go to use the tools.
The regulatory architecture of behavioral health integration was rebuilt between 2023 and 2026
The clearest evidence of how much has changed is the regulatory record. In December 2022, the Mainstreaming Addiction Treatment Act, folded into the Consolidated Appropriations Act of 2023, eliminated the DATA-Waiver (the “X-waiver”) that for two decades had required a special federal credential to prescribe buprenorphine for opioid use disorder. Any clinician with a standard DEA registration that includes Schedule III authority can now prescribe it, with no patient caps, subject to state law.
In February 2024, SAMHSA finalized the first substantial update to opioid treatment program (OTP) regulations in more than 20 years. The rule, effective April 2, 2024 with an October compliance date, made permanent several flexibilities first granted during the COVID-19 emergency: take-home doses of methadone for stabilized patients, treatment initiation by telehealth (buprenorphine by audio-only or audio-visual, methadone by audio-visual), and the removal of the longstanding requirement that a patient have a one-year history of addiction before admission. Where state law allows, nurse practitioners and physician assistants can now order medications for opioid use disorder inside an OTP.
That same month, HHS finalized a long-sought alignment of 42 CFR Part 2, the federal confidentiality rule for SUD records, with HIPAA. The rule (effective April 16, 2024, with compliance and enforcement beginning February 16, 2026) lets a single patient consent cover future uses and disclosures for treatment, payment, and health care operations, rather than forcing a separate signed consent for each disclosure. The point was practical: the old Part 2 regime, more stringent than HIPAA, made it cumbersome to share addiction records inside an integrated care team, and providers had complained about that friction for years. The enforcement date for the revised Part 2 arrived only this past February, which means the integration the rule was meant to enable is just now becoming fully operational.
Underpinning all of it is the Certified Community Behavioral Health Clinic. Created under the Protecting Access to Medicare Act in 2014 and expanded by the Bipartisan Safer Communities Act in 2022 (which adds ten states to the Medicaid demonstration every two years), the model was made a permanent optional Medicaid state plan benefit by the Consolidated Appropriations Act of 2024. CCBHCs are built around exactly the proposition this beat keeps returning to: mental health, substance use, and physical health coordinated in one place and paid through a cost-based rate rather than fee-for-service volume. Acuity’s coverage of the dual-diagnosis billing silos has documented how rare that kind of alignment remains elsewhere in the system.
Medication access for opioid use disorder expanded on paper, but uptake tells a more complicated story
The gap between what the rules now permit and what is actually happening in exam rooms is the central tension of integration in 2026. Eliminating the X-waiver expanded the pool of clinicians legally able to prescribe buprenorphine from roughly 130,000 to about 1.8 million, a thirteen-fold increase. But a 2025 analysis in the American Journal of Preventive Medicine, examining national dispensing data, concluded that the change alone was insufficient to meaningfully increase buprenorphine access: the number of patients receiving the medication did not surge, and in early 2023 it actually dipped. Researchers attributed part of the stagnation to timing, because the X-waiver repeal coincided with the unwinding of pandemic-era continuous Medicaid enrollment, which knocked millions off coverage just as the prescriber pool widened.
The lesson, repeated across integration, is that permission is necessary but not sufficient. A clinician newly allowed to prescribe buprenorphine may still lack the training, the confidence, the staffing, or the reimbursement to do it. The same pattern shows up in the collaborative care model (CoCM), the most evidence-backed approach to embedding behavioral health in primary care, validated in more than 90 randomized controlled trials. Acuity has reported that commercial-market CoCM penetration grew roughly 27-fold between 2018 and 2023, yet that growth is concentrated in pockets of champions and tracks almost entirely with whether a given state’s Medicaid program pays for it. As of mid-2025, 36 state Medicaid programs covered the CoCM billing codes; the rest lag across every payer.
Telehealth has been the other great enabler, and here too the policy is durable but unsettled. A DEA and HHS final rule made buprenorphine telemedicine prescribing permanent at the end of 2025, allowing up to six months of virtual treatment for a new patient before an in-person visit, while the broader set of pandemic-era flexibilities for controlled substances was extended only through December 31, 2026. As Acuity noted in its coverage of governing by extension, more than seven million controlled-substance prescriptions were issued via telemedicine in 2024 without a prior in-person visit, which means the difference between a permanent rule and another temporary one is not academic for the patients depending on it.
The behavioral health financing foundation is contracting just as integration matures
The uncomfortable backdrop to all of this is that the bill for integration is coming due at the same moment the country is deciding to spend less on it. The One Big Beautiful Bill Act, signed July 4, 2025, cuts federal Medicaid funding by roughly $1 trillion over a decade, with the Congressional Budget Office projecting that 10 million or more people will lose coverage. Medicaid is the single largest payer of mental health and substance use services in the United States, accounting for about a quarter of all such spending, so a contraction of the Medicaid rolls is a contraction of the patient base for every integration model that depends on stable enrollment. Work requirements take effect in January 2027 and six-month eligibility redeterminations at the end of 2026, both of which create the kind of mid-treatment coverage gaps that are especially dangerous in addiction care, where an interruption in buprenorphine can mean a return to use. Acuity has examined the looming six-month redetermination rule in detail.
The federal infrastructure is also in flux. In March 2025, HHS announced it would merge SAMHSA, the agency that has led the national behavioral health response since 1992, with the Health Resources and Services Administration into a new Administration for a Healthy America. Proponents framed the merger as a step toward integration itself; critics warned about the loss of dedicated behavioral health expertise during a crisis. The turbulence has been concrete: the administration withdrew roughly $1.3 billion in unspent block grant funds in early 2025, and on January 13, 2026, SAMHSA abruptly terminated hundreds of grants worth approximately $2 billion before reinstating them the next evening after bipartisan pushback. For providers trying to plan multi-year integration investments, that whiplash is its own kind of barrier. Acuity has tracked how the CMS Medicaid work-requirement rule ties behavioral health exemptions to a beneficiary’s ability to work, another front on which coverage and care intersect.
Where behavioral health integration actually stands in 2026
So where are we now? The honest answer is that the United States has, over three years, assembled most of the legal and clinical architecture that integration advocates spent two decades asking for. The X-waiver is gone. Methadone and buprenorphine are more accessible than at any point in the medication’s history. Addiction records can move through a care team without a separate consent at every step. The clinic model designed for whole-person behavioral health is now a permanent Medicaid benefit. And the overdose curve, for the first time, is bending down.
What is missing is not knowledge, or even, mostly, regulation. It is durable financing and stable institutions. The same months that produced permanent telehealth prescribing for buprenorphine also produced the largest Medicaid cuts in the program’s history and the most significant disruption to the federal behavioral health agency in a generation. Integration, in other words, has become a question of whether the country will pay for what it has already decided it knows how to do. Acuity’s ongoing coverage of behavioral health regulation will track which way that resolves. The tools are built. The test in 2026 is whether they get used, and by whom.
